The observations that TIM3 marks dysfunctional phenotype of CD8+ T cells in both experimental models and cancer patients and that TIM3 + Tregs are found solely in tumor tissue have made TIM3 pathway a very suitable target for anticancer immunotherapy based on immune checkpoint blockade [151]. This evidence concerns the gene CD8A and neoplasm.